SY-4798 |
|
Phase 1 Clinical |
Shouyao Holding (Beijing) Co Ltd |
Solid tumours |
Details
|
BPI-43487 |
BPI-43487 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular |
Details
|
HS-10340 |
HS-10340 |
Phase 1 Clinical |
Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Solid tumours |
Details
|
JAB-6343 |
|
Phase 1 Clinical |
Jacobio Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
SYHX-2005 |
SYHX-2005; SYHX2005 |
Phase 1 Clinical |
Cspc Ouyi Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Roblitinib |
FGF-401; NVP-FGF401 |
Phase 2 Clinical |
Novartis Pharma Ag |
Neoplasms; Carcinoma, Hepatocellular |
Details
|
Gunagratinib |
ICP-192 |
Phase 2 Clinical |
Beijing Tiancheng Pharmaceutical Technology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Lung Neoplasms |
Details
|
LY-2874455 |
LY-2874455 |
|
Eli Lilly And Company |
|
Details
|
INCB-62079 |
INCB-62079; INCB-062079 |
|
Incyte Corp |
|
Details
|
H3B-6527 |
H3B-6527 |
|
H3 Biomedicine Inc |
|
Details
|
EVER-4010001 |
EVER-4010001 |
Phase 2 Clinical |
EverNov Medicines (Zhuhai Hengqin) Co Ltd |
Solid tumours |
Details
|
ZSP-1241 |
ZSP-1241 |
Phase 1 Clinical |
Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd |
Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Colorectal Neoplasms |
Details
|
ASP-5878 |
ASP-5878 |
|
Astellas Pharma Inc |
|
Details
|
U3-1784 |
U3-1784 |
|
U3 Pharma |
|
Details
|
Fisogatinib |
BLU-554; CS-3008 |
Phase 2 Clinical |
Blueprint Medicines Corp |
Carcinoma, Hepatocellular |
Details
|
Rogaratinib |
BAY-1163877 |
Phase 2 Clinical |
Bayer AG |
Carcinoma, Transitional Cell; Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung |
Details
|
ODM-203 |
ODM-203 |
|
Orion Corp |
|
Details
|
ICP-105 |
ICP-105 |
Phase 1 Clinical |
Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd |
Liver Neoplasms; Solid tumours |
Details
|
SC-0011 |
SC-0011 |
Phase 1 Clinical |
Shijiazhuang Zhikang Hongren New Drug Development Co Ltd |
Solid tumours |
Details
|
Aldafermin |
M-70; NGM-282 |
Phase 2 Clinical |
Ngm Biopharmaceuticals |
Liver Cirrhosis, Biliary; Constipation; Non-alcoholic Fatty Liver Disease; Renal Insufficiency; Irritable Bowel Syndrome; Fibrosis; Cholangitis, Sclerosing; Diarrhea; Hepatic Insufficiency; Diabetes Mellitus; Malabsorption Syndromes |
Details
|
ABSK-011 |
ABSK-011 |
Phase 2 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
HS-236 |
HS-236 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Solid tumours |
Details
|